SCHEMBL2536657

SCHEMBL2536657

CONN(Cc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 3/20 0.56
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
CTSL P07711 2/20 0.44
CTSB P07858 2/20 0.44
CTSS P25774 2/20 0.44
RIPK1 Q13546 2/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41
TSHR P16473 1/20 0.41
ITGA4 P13612 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783730 0.85 AKT1 (0.62) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL22649519 0.78 AKT1 (0.54) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL3819098 0.78 AKT1 (0.52) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL26696920 0.77 AKT1 (0.53) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL4370061 0.77 AKT1 (0.50) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7190668 0.76 RIPK1 (0.57) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6624013 0.76 RIPK1 (0.57) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL14858226 0.76 AKT1 (0.49) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL24736794 0.75 AKT1 (0.54) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL2061999 0.75 AKT1 (0.50) AKT1HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044067-B2 Isoquinolines as IGF-1R inhibitors ANALYTECON S.A. (CH) 2011-10-25 US disclosed
US-20090099229-A1 Isoquinolines as IGF-1R Inhibitors ANALYTECON S.A (CH) 2009-04-16 US disclosed
EP-1931636-A1 ISOQUINOLINES AS IGF-1R INHIBITORS Analytecon S.A. (CH) 2008-06-18 EP disclosed
WO-2007029106-A1 ISOQUINOLINES AS IGF-1R INHIBITORS ANALYTECON SA (CH) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099229-A1 Isoquinolines as IGF-1R Inhibitors IGF1R, IGFBP1, IGF2BP1 AKT1 1726/4885HDAC3 2466/4885HDAC1 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.